Qualigen Therapeutics (QLGN) News Today → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free QLGN Stock Alerts $0.30 -0.02 (-6.34%) (As of 04/22/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineQualigen Announced An Agreement With Marizyme To Commercialize DuraGraftmarkets.businessinsider.com - April 16 at 9:47 AMMarizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™finance.yahoo.com - April 16 at 9:47 AMQualigen presents preclinical novel cancer inhibitors at AACR 2024uk.investing.com - April 12 at 9:35 AMQualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meetingglobenewswire.com - April 10 at 8:00 AMQualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meetingglobenewswire.com - April 9 at 8:00 AMQualigen Therapeutics Inc Ordinary Shares QLGNmorningstar.com - February 22 at 3:38 PMQualigen Therapeutics Inc (QLGN)uk.investing.com - February 7 at 11:54 PMQLGN: Dosing Begins in Phase 1 Trial of QN-302…finance.yahoo.com - November 27 at 6:06 PMQualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023finance.yahoo.com - November 14 at 8:23 PMQualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumorsfinance.yahoo.com - November 7 at 9:19 AMPoster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancerfinance.yahoo.com - October 23 at 1:03 PMQualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023finance.yahoo.com - September 27 at 1:05 PMQualigen Therapeutics Inc (7R9.DU)ca.finance.yahoo.com - September 2 at 12:01 AMQLGN: Receives U.S. FDA IND Clearance; Phase 1 Trial to Initiate 2H23…finance.yahoo.com - August 30 at 6:57 PMQualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumorsfinance.yahoo.com - August 17 at 6:08 PMQualigen Therapeutics GAAP EPS of -$0.69, revenue of $1.62Mmsn.com - August 15 at 2:55 PMQualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023finance.yahoo.com - August 15 at 2:55 PMQualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumorsfinance.yahoo.com - August 1 at 11:57 AMQualigen Therapeutics Divests FastPack® Diagnostics Businessfinance.yahoo.com - July 24 at 8:43 AMQLGN: Data for Pan-RAS Platform Presented at ASCO…finance.yahoo.com - June 14 at 7:12 PMPoster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meetingtechnews.tmcnet.com - June 6 at 9:10 AMPoster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meetingfinance.yahoo.com - June 5 at 1:08 PMQualigen Therapeutics GAAP EPS of -$0.78, revenue of $1.61Mseekingalpha.com - May 18 at 9:54 AMQualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023finance.yahoo.com - May 16 at 10:33 AMQLGN: IND for QN-302 to be Submitted in Mid-2023…finance.yahoo.com - May 12 at 2:06 PMQualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 2 at 9:10 PMQualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meetingfinance.yahoo.com - May 2 at 10:31 AMQualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filingfinance.yahoo.com - April 21 at 6:57 PMQualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FLfinance.yahoo.com - April 18 at 10:43 AMQualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FLfinance.yahoo.com - April 18 at 10:43 AMQualigen Therapeutics, Inc.: Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Officefinanznachrichten.de - March 21 at 2:06 PMComposition of Matter Patent for QN-302 Granted by United States Patent and Trademark Officefinance.yahoo.com - March 21 at 9:05 AMQualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023finance.yahoo.com - March 15 at 2:31 PMQualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conferencefinance.yahoo.com - March 9 at 9:02 AMData on Potential Biomarker for Qualigen Therapeutics’ Lead Program QN-302 Published in Peer-Reviewed Journal Moleculesfinance.yahoo.com - March 8 at 9:34 AMQualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholdersfinance.yahoo.com - February 1 at 1:03 PMQualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302finance.yahoo.com - January 24 at 1:26 PMQualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communicationsfinance.yahoo.com - January 23 at 3:34 PMQualigen Therapeutics' QN-302 Receives FDA's Orphan Drug Designationmarketwatch.com - January 10 at 9:48 AMQualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancerfinance.yahoo.com - January 10 at 9:48 AMQualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platformfinance.yahoo.com - January 5 at 10:40 AMQualigen Therapeutics, Inc.: Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rulefinanznachrichten.de - December 13 at 7:09 AMQualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Ruletechnews.tmcnet.com - December 12 at 8:46 AMQualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumorsfinance.yahoo.com - December 7 at 3:22 PMQLGN: Encouraging Preclinical Data Presented for QN-302 and RAS Inhibitor…finance.yahoo.com - December 1 at 7:30 PMQualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Splitfinance.yahoo.com - November 22 at 8:01 PMQualigen Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - November 17 at 6:56 AMQualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 15 at 10:59 AMQLGN Qualigen Therapeutics, Inc.seekingalpha.com - October 21 at 10:31 PMQualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institutefinance.yahoo.com - October 19 at 4:56 PM Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Global crypto currency reset (41 major banks signed up) (Ad)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. QLGN Media Mentions By Week QLGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QLGN News Sentiment▼1.330.46▲Average Medical News Sentiment QLGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QLGN Articles This Week▼20▲QLGN Articles Average Week Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INM News Today LSDI News Today CMRA News Today DRMA News Today PBLA News Today GLMD News Today BPTH News Today CMND News Today GRI News Today HSTO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QLGN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
